This association, and the recent description of FOXA1 as a determinant of chemotherapy resistance in breast cancer cells [27], strengthen the rationale of trials to evaluate the combination of androgen receptor-targeting agents with new-generation anti-HER2 targeted therapies. The gene discussed is FOXA1; the disease is breast carcinoma.